Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0C6MS
|
||||
| Former ID |
DND000083
|
||||
| Drug Name |
PF-04991532
|
||||
| Indication | Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] | Phase 2 | [1] | ||
| Company |
Pfizer
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Glucokinase | Target Info | Activator | [2], [3] | |
| KEGG Pathway | Glycolysis / Gluconeogenesis | ||||
| Galactose metabolism | |||||
| Starch and sucrose metabolism | |||||
| Amino sugar and nucleotide sugar metabolism | |||||
| Butirosin and neomycin biosynthesis | |||||
| Metabolic pathways | |||||
| Biosynthesis of antibiotics | |||||
| Carbon metabolism | |||||
| Insulin signaling pathway | |||||
| Insulin secretion | |||||
| Prolactin signaling pathway | |||||
| Glucagon signaling pathway | |||||
| Type II diabetes mellitus | |||||
| Maturity onset diabetes of the young | |||||
| Central carbon metabolism in cancer | |||||
| Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | ||||
| HIF-1-alpha transcription factor network | |||||
| PathWhiz Pathway | Nucleotide Sugars Metabolism | ||||
| Starch and Sucrose Metabolism | |||||
| Galactose Metabolism | |||||
| Trehalose Degradation | |||||
| Reactome | Regulation of gene expression in beta cells | ||||
| Glucose transport | |||||
| Glycolysis | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Glycolysis and Gluconeogenesis | |||||
| MAPK Signaling Pathway | |||||
| Regulation of beta-cell development | |||||
| Metabolism of carbohydrates | |||||
| Hexose transport | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01338870) Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes. U.S. National Institutes of Health. | ||||
| REF 2 | The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One. 2014 May 23;9(5):e97139. | ||||
| REF 3 | Comparison of the circulating metabolite profile of PF-04991532, a hepatoselective glucokinase activator, across preclinical species and humans: potential implications in metabolites in safety testing assessment. Drug Metab Dispos. 2015 Feb;43(2):190-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.